Eliem Therapeutics Gross Profit 2021-2024 | CLYM
Eliem Therapeutics gross profit from 2021 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Eliem Therapeutics Annual Gross Profit (Millions of US $) |
2023 |
$ |
2022 |
$ |
2021 |
$ |
2020 |
$ |
Eliem Therapeutics Quarterly Gross Profit (Millions of US $) |
2024-06-30 |
|
2024-03-31 |
|
2023-12-31 |
|
2023-09-30 |
|
2023-06-30 |
|
2023-03-31 |
|
2022-12-31 |
|
2022-09-30 |
|
2022-06-30 |
|
2022-03-31 |
|
2021-12-31 |
|
2021-09-30 |
|
2021-06-30 |
|
2021-03-31 |
|
2020-12-31 |
|
2020-09-30 |
|
2020-06-30 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-DRUGS |
$0.342B |
$0.000B |
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|